GBIO

Generation Bio Co

GBIO, USA

Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise mechanism of target engagement could unlock a series of high-value historically undruggable disease-driving genes in autoimmunity. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

https://generationbio.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
GBIO
stock
GBIO

Here's Why We're A Bit Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation Yahoo Finance

Read more →
GBIO
stock
GBIO

Companies Like Generation Bio (NASDAQ:GBIO) Could Be Quite Risky simplywall.st

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$9.3333

Analyst Picks

Strong Buy

3

Buy

1

Hold

3

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

0.72

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-10.92 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-4.53 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-3,304.89 %

Low 5%

High 15%

Debt to Equity

-

Very Low

1.41

Low 1

High 0.3

Investors

* Institutions hold a combined 65.73% of the total shares of Generation Bio Co

1.

T. Rowe Price Associates, Inc.

(12.5641%)

since

2025/06/30

2.

US Small-Cap Growth II Equity Comp

(7.0597%)

since

2025/06/30

3.

T. Rowe Price New Horizons

(7.0597%)

since

2025/07/31

4.

Siren, L.L.C.

(4.4078%)

since

2025/06/30

5.

Renaissance Technologies Corp

(3.8316%)

since

2025/06/30

6.

FMR Inc

(3.4825%)

since

2025/06/30

7.

Vanguard Group Inc

(3.4123%)

since

2025/06/30

8.

Vanguard Total Stock Mkt Idx Inv

(2.2628%)

since

2025/07/31

9.

T. Rowe Price Health Sciences

(2.0974%)

since

2025/07/31

10.

BlackRock Inc

(1.7245%)

since

2025/06/30

11.

T. Rowe Price New Horizons Tr-A

(1.5836%)

since

2025/06/30

12.

Goldman Sachs Group Inc

(1.5798%)

since

2025/06/30

13.

Millennium Management LLC

(1.5761%)

since

2025/06/30

14.

Yiheng Capital LLC

(1.5667%)

since

2025/06/30

15.

Morgan Stanley - Brokerage Accounts

(1.3552%)

since

2025/06/30

16.

UBS Group AG

(1.3138%)

since

2025/06/30

17.

Bank of America Corp

(1.2946%)

since

2025/06/30

18.

Militia Capital Partners, LP

(0.8052%)

since

2025/06/30

19.

Squarepoint Ops LLC

(0.7695%)

since

2025/06/30

20.

Geode Capital Management, LLC

(0.7395%)

since

2025/06/30

21.

Vanguard Institutional Extnd Mkt Idx Tr

(0.7324%)

since

2025/07/31

22.

TD Asset Management Inc

(0.5058%)

since

2025/06/30

23.

Galileo - Biotech Innovation Fund S USD

(0.4646%)

since

2025/02/28

24.

Fidelity Extended Market Index

(0.3793%)

since

2025/07/31

25.

Susquehanna International Group, LLP

(0.3701%)

since

2025/06/30

26.

Charles Schwab Investment Management Inc

(0.3517%)

since

2025/06/30

27.

Fidelity Global Micro-Cap F

(0.3266%)

since

2025/06/30

28.

State Street Corp

(0.306%)

since

2025/06/30

29.

Citadel Advisors Llc

(0.2853%)

since

2025/06/30

30.

T. Rowe Price U.S. Equities Tr

(0.2637%)

since

2025/06/30

31.

TD Health Sciences - I

(0.2529%)

since

2024/12/31

32.

Goldman Sachs Small Cp Val Insghts Instl

(0.249%)

since

2025/04/30

33.

Extended Equity Market Fund K

(0.1511%)

since

2025/06/30

34.

NT Ext Equity Mkt Idx Fd - NL

(0.1087%)

since

2025/06/30

35.

T. Rowe Price US Small-Cap Growth Equity

(0.1044%)

since

2025/06/30

36.

Northern Trust Extended Eq Market Idx

(0.0862%)

since

2025/06/30

37.

NT Ext Equity Mkt Idx Fd - L

(0.0862%)

since

2025/06/30

38.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0844%)

since

2025/06/30

39.

NT Col R2000 Val Idx Fd -DC -L -TierFour

(0.0716%)

since

2025/03/31

40.

JHFunds2 Health Sciences NAV

(0.0677%)

since

2025/01/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2025-09-30

EPS Actual

-0.82

EPS Estimate

-0.28

EPS Difference

-0.54

Surprise Percent

-192.8571%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4.5)
Defensive
Moderately Defensive(6)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(3.8)
GARP
Fair GARP(3.5)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(3.5)
Net Net
Possible Net-Net(3.5)
Quality
Low Quality Business(1.5)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.